Although surgery, radiology, and anticancer chemicals have been effective in the treatment of cancer, the immunologic phase of therapy deserves more effort and thought, because the possibilities are considerable. However, the immunologic phase is so complicated that, without the advances made during the past few years, little could be expected from immunology. The focus of this paper is on the immunosuppression produced by major cancer operations, at which time the patient needs immunologic help.
Unfortunately, we have no accurate way of determining whether or not the patient's immunologic status is good enough to kill a moderate number of cancer cells escaping from the primary. Therefore, it appears to us that we must always maintain strict precautions lest that day has already arrived when escape of a few cancer cells will result in.a metastasis.
To test the viability of cells in the circulating system of animals, Zeidman and Bass3 injected a suspension of cancer cells into the ear veins of rabbits. They immediately aspirated aortic blood and injected it intravenously into normal rabbits, in which tumors developed. Those authors concluded that this transpulmonary passage takes place in the human being. In a similar experiment, t on ass on^ injected the blood of mice with advanced T240 or TI50 cancer into 15 normal mice; eight of these mice subsequently developed tumors. Numerous au'thors2 have shown that, if venous invasion can be found microscopically, the 5-year survival will be much lower than in patients without venous invasion.
Implantation of Cancer Cells
Implantation of cancer cells is closely related to the status of immune reserve, which is a major factor in this presentation. This mechanism of spread may be spontaneous or iatrogenic.
Spontaneous implantation is encountered often by surgeons operating on patients with cancer of colon, ovary, and other organs in the abdominal cavity who find miliary lesions on the mesothelial surface, preventing a curative resection. Likewise, miliary implants are often found in the thoracic cavity secondary to tumors of the lung and elsewhere. These implants occasionally occur after the patient's host resistance has deteriorated to the point that his/her protective mechanism no longer destroys cells that escape from the primary. Such implants rarely occur in the skin or mucous membrane, unless there is a tear in the skin or mucous membrane.
Beahrs and associatesS reported an example of implantation that demonstrated how vigorous and virulent cancer cells can be. They had four patients with adenocarcinoma in the scar of a hemorrhoidectomy wound. All of these patients had cancer of the rectum or sigmoid which was removed after the adenocarcinoma in the hemorrhoidectomy scar was found. None of the four patients had their hemorrhoidectomy operation at the Mayo Clinic. The authors concluded that the tumors in the anal region were implants from the tumors in the rectum and colon.
Iatrogenic implantation was recently summarized by Sugarbaker and Ketcham as follows: "Release of cancer cells into the surgical wound can result in implantation and growth of these cells, creating miliary new deposits. This important type of iatrogenic tumor dissemination causes many local recurrences. Therefore, wide margins to the extent of radical amputations have been recommended in some cancers to control these regional subclinical extensions of di~ease.~ Iatrogenic implantation has been recognized for more than 100 years. G e r~t e r ,~ who was one of the first to report on this surgical complication, reported a patient with a melanoma ulcer extending deeply on the plantar surface of the foot. This area was excised and the wound healed completely but, within a few months, small purplish pigmented nodules appeared in and adjacent to the scar. He warned that operations may occasionally disseminate the tumor and emphasized the danger of disseminating tumor cells by manipulation during examination and during operation.
Cucin and Gastrin8 report a patient having a modified radical mastectomy at which time a nipple was transplanted to the left groin, to be transplanted later to the breast area. Several months later a nodule appeared in the area of the transplanted nipple; biopsy revealed recurrent cancer.
Ranbarger and associatesg report their experience with 250 patients with cancer of the rectum, 23.6% of whom had perforation of the rectum during the operation, thus exposing the operative wound to cancer cells. In Dukes A patients, the cure rate was not affected by this contamination. It could not be, because the immunologic resistance of these Dukes A patients could kill any disseminated cells of moderate quantity. In the Dukes B tumors, the incidence of local recurrence was 25.9%, contrasted to 8.1% in the patients without perforation. In patients with Dukes B and C tumors, the incidence of distal recurrence was 57% in patients with perforation, compared to 34% in the nonperforated cases. There was a survival rate of only 31% in the perforated cases, compared to 46% in the nonperforated cases. Details of iatrogenic implantation have been discussed elsewhere.'
In spite of the reports of innumerable types of iatro-genic implantation, too many surgeons are not sufficiently careful about the precautions in preventing them. The role of biopsy has been discussed elsewhere,' but we wish to reemphasize the experience and opinions expressed by urban.'' Often there is a delay of 2 weeks or more after biopsy (of the breast) before the definitive operation is performed. Many surgeons would contend this delay would be too short to exert any role in the final outcome. However, Urban reports that the 5-year survival rate clinically free of disease was 20% better in patients having their radical operation immediately after the biopsy than it was in the patients having their operation 2 weeks or more after biopsy. In patients with negative nodes (stage l), there was no difference in the ultimate results. Actually, there could not be because these patients in stage 1 are "killing" all cells escaping from the primary at the time of the biopsy. In Stage 2 patients with positive axillary or internal mammary nodes, the 5-year survival rate of patients treated by immediate operation was twice as high as in patients operated on 2 weeks or more after biopsy. The immunosuppression produced by a major operation may be a factor in the results, because the patients having delay between biopsy and radical operation have the possibility of more days of immunosuppression than the other group. However, this would imply that the biopsy and its consequent worry would be of sufficient trauma to cause immunosuppression. It scarcely seems possible that this slight trauma could cause immunosuppression. Urban states "aspiration biopsy should not be used as an outpatient procedure to rule out the presence of cancer. It is significant only when it is positive. A negative aspiration does not rule out the presence of breast cancer." This paper supports Urban's conclusion that biopsy with frozen section and immediate mastectomy still represents the best care for breast cancer.
Types of Immunologic Protection
There are two types of immunologic reaction protecting the host against cancer, cellular and humoral. Both are found in the blood stream. Removal of primary lymphoid organs before the development of T or B lymphocytes damages the body's capacity to develop certain immune responses. Removal of these organs in the adult does not interfere significantly with immunologic functions. Thymectomy in mammals decreases cellular immunity, but does not significantly interfere with the development of immunoglobulins producing cells involved in production of humoral antibodies, although it does interfere with some types of antibody responses. The two cells may act alone, but more commonly they "act together with either of the other lymphocytes of the same (or different) class or with 11 nonlymphocyte accessory cells such as the macrophages."I '
Cell-mediated Immunity
Two types of small lymphocytes are responsible for the cell-mediated immunity (CMI) possessed by the human being.
The B cells are derived from the bursa of Fabricus in birds and probably from the bone marrow of mammals. They carry immunoglobulin receptors and are responsible for the formation of specific antibodies. It may be difficult to distinguish between the two cells; important in this identification is the surface marker (immunoglobulin) possessed by the B lymphocytes, which is capable of making antibodies. Presumably, one lymphocyte can produce antibody of only one immunoglobulin on their surface. Aside from immunoglobulins as surface markers, B lymphocytes may have receptors for the third component of complement. It has been suggested that B cells can be influenced by so-called T-dependent antigens in the absence of T cells. The immunoglobulin on B cells is usually demonstrable by direct or indirect fluorescence. It is believed that immature B cells synthesize IgM or IgD (or both), whereas more mature B cells give rise to IgG, IgA, or IgE.I2 T cells originating in the thymus comprise about 60% of lymphocytes in the blood stream. They are cytotoxic and are important in the host's protection against cancer. In the lymph nodes they are found in the deep cortical areas; in the spleen they are found in the periarteriolar sheath.I3 They have surface markers that aid in their identity. In addition to their cytotoxic effect, it is probable that they release soluble factors (lymphokines) that produce direct toxic effects on cancer cells, sometimes perhaps by aiding B cells.
EpsteinI4 has suggested that the T cell is involved in a blastogenic factor "which stimulates activation of additional lymphocytes to blastic transformation, and a transfer factor which is immunologically specific for recruiting new lymphocytes to the sensitized state." There is also evidence that, under certain circumstances, a T cell subpopulation also suppresses B cell immune responses.15J6
In addition to the cytotoxic T cell, there are two additional lymphocytes that have cytotoxic effect. One such lymphocyte is the K or killer cell. According to Morton and Wells,'' this cell is able to mediate antibodydependent cellular cytotoxicity. However, it is not a thymus-derived cell, and must have a receptor for the Fc portion of immunoglobulin. The lethal effect it produces is not dependent on complement and is not phagocytic. The NK cell is another important lymphocyte which Talmadge and associatesI8 indicate may act as a surveillance cell by supplying a first line defense against aberrant cells. NK activity may be a defense mechanism important in metastatic development.
Humoral Immunity
Humoral immunity depends on the presence of tumorspecific antigens, which are capable of inducing antibodies. The following tumors have specific antigens:
Breast Morton and Wells state that most, if not all, human cancers possess tumor-associated antigens capable of producing a host-immune response. "Each patient's serum antibodies or lymphocytes react not only with his own tumor but also with other tumors of the same histologic type from different patients."17 Many investigators believe that primary tumors give rise to both antibody-and cell-mediated reactions as protective mechanisms in their host.
There is evidence that detectable antibodies are more apt to be found in early localized tumors than in late tumors. For example, ~e w i s~' has reported that antibody decrease often is noted several weeks before metastases develop, and that the size of tumor mass has no relationship to the amount of detectable antibody. He noted that patients with a large amount of localized tumor are apt to be antibody-positive. On the other hand, patients with dissemination of cancer beyond the lymph nodes are apt to have no detectable antibody.
Morton and Wells have stated that "the effectiveness of the hosts' immune defense is limited because the growing neoplasm seems to be able to evade an immune attack by producing specific and nonspecific immunosuppression in the cancer patient to enhance its growth."17 Evidently, soluble tumor-associated antigens are being shed constantly into the blood and can inhibit the cellular-mediated destruction of tumor cells in vitro, A growing neoplasm often produces humoral factors equivalent to nonspecific suppression of the cancer patient's immune system, Surgery may act as immunotherapy. When the tumor mass is excised, the host's immune mechanism may then be able to destroy a small number of tumor cells encountered in micrometastases. In other words, some patients will be able to destroy a small number of cells in miliary metastases after operative removal of the tumor mass; others will not, depending on the status of the host's immune system.
The use of monoclonal antibodies may add much to the accuracy of immunologic diagnosis of cancer; it utilizes a new approach to localization of primary and metastatic tumors. This technique was originally described by Kohler and Milstein.21 Innumerable reports utilizing this technique have been reviewed by Epstein.14 This includes radioimaging of tumors in mice by use of an iodine-labeled monoclonal antibody reported by several investigators. "Similarly, gamma iay scintigraphy has been used to localize metastases in patients receiving radiolabeled monoclonal antibody to tumor-associated antigens."14 Within the past 5 or 6 years, numerous authors have produced monoclonal antibodies "to antigens associated with melanoma, colorectal carcinoma, neuroblastoma, glioma, mammary carcinoma, leukemia, sarcoma, carcinoembryonic antigen, and alpha-feto protein.14
Immunoglobulins
Some immunoglobulins are very important in the destruction of cancer cells, some destroy bacteria, and others are important in the rejection phenomenon. The function is not clear in others. In cancer patients, most of these immunoglobulins are found in low or high levels under variable circumstances. There is not complete agreement by the investigators.
Basic Data
IgG comprises 70% of serum immunoglobulins. It is important as a protective mechanism. Its chemical structure and function activate a series of serum proteins known as the complement system, which assist the antibody molecule in "lysing the antigen." IgG antibodies neutralize toxins and viruses; they also stimulate phagocytic cells to help destroy bacteria and cancer cells. Every normal human being synthesizes four different subclasses IgG1, IgG2, IgG3, and IgG4, numbered in order of diminishing relative abundance. 22 Z g A is found chiefly in saliva, secretions of the gastrointestinal tract, and in the respiratory tract. It is made by lymphocytes and plasma cells. Very little is found in the serum. The chief activity of IgA is to agglutinate bacteria and viruses.
IgM is the largest of the immunoglobulins, having a molecular weight of 900,000. These antibodies are the first formed after immunization; they agglutinate bacteria and red cells.
ZgE is difficult to distinguish from IgA and is present only in small quantities in the serum. However, allergic individuals and patients with parasites produce more antibodies of this type than normal individuals.
ZgD is found only in small quantities in the serum. Its function is not clear. Like IgM, it is found on the cell surface of some lymphocytes.
Clinical Data
Immunoglobulin A levels were determined in the urine of 13 patients with bladder cancer by Betkerur and associate^.^^ These levels were significantly higher than in patients with urinary tract infection or in normal individuals. An elevation of immunoglobulin IgA was found by Baskies and associates24 in patients with nasopharyngeal carcinoma. Serum immunoglobulins of three classes' studies were greater in cancer patients than in normal subjects (IgA, p < 0.05; IgG, p c 0.0001; IgM, p < 0.01). The levels for the three classes in stage I and I1 patients did not differ from data in normal subjects. The levels of IgA in stages 111 and IV were significantly greater than in patients with stage I and I1 tumors. Goodale and associates25 analyzed the pancreatic fluid at the time of endoscopy. The IgA and IgG levels were significantly greater in the patients with pancreatic cancer; the IgM level was of borderline significance.
Serum immunoglobulins were measured before surgery in 102 patients with colorectal carcinoma by Slater and a s s o~i a t e s .~~ There was no difference in the values of IgA, IgM, or IgG between stages. However, there was an association between advanced stages of disease and a combination of low levels of IgA or high levels of IgM. The ratio of IgA/IgM was found to be lower in advanced cancer. Low levels of IgA and high levels of IgM might represent an altered immune response, and, thus, be a prognostic indication.
Using the direct immunofluorescence test, lesions from 266 human breast specimens were analyzed by McCarty and associates2' for the presence of IgG, IgM, and IgG. There were 66 benign lesions in this group. They found a statistically significant association of IgA and IgM in benign lesions, whereas a statistically significant amount of IgG was found in malignant lesions.
Interaction Between Immune System Components
There is an interaction of cell-mediated immunity and noncellular or humoral immunity. At the same time, as depicted in Figure 1 , an interaction between different cell types exists. Furthermore, several cell types produce immunoregulators, or lymphokines, which exert a variety of influences on the system. This elaborate and complex system has built-in feedback pathways acting as governors for both immunostimulation and immunosuppression. Thus, one hastens to agree with the concluding statement of Keller et a1.,28 who demonstrated that interferon (IF) in vitro augmented the natural killer (NK) and macrophage (M) cytotoxicity for tumor cells. However, IF did not affect NK-cytoxicity and, at the same time, phorbal ester (a tumor-promoting agent) prevented augmentation of cytolytic capability by Mactivating lymphokines and by IF. Keller et al. concluded that this is "a complex system for which simple explanations are risky." 28 As the background is developed to help understand mechanisms of action and potential therapies for immunostimulation, it is important to remain cognizant of the problems pointed out by Altman and ~a t z .~' They emphasized that one of the major problems with lymphokine preparations is the heterogenicity of cell populations used to produce lymphokines and the limited amounts of material for structural analysis. A similar problem exists in studies of subsets obtained from peripheral blood lymphocytes (i.e., the difficulty in obtaining a pure subset of lymphocytes and an insufficient quantity).
These reservations illustrate why the following consideration of the checks and balances of immune responsiveness cannot be all-inclusive nor complete. Other lymphokines and the molecular basis for mediator and cellular interactions will continue to change and refine these preliminary tenets.
Cell-Cell Interactions
These discussions focus on killer cells (K), natural killer cells (NK), macrophages (M), B lymphocytes (B), T-helper/inducer lymphocytes (Th), and T-suppressor/ cytotoxic lymphocytes (Ts, Tcyto).
NK cell activity has been studied extensively in cancer patients and its relationship to other cells is not wellknown, but it may function both in immune surveillance and as an effector cell. K cells do interact with other components of the immune system in their role in antibody-dependent cellular cytotoxicity (ADCC).I7 Thus, antibody production and availability are important to K cell function.
Mononuclear phagocytes and macrophages are comprised of a yet undefined variety of subsets. They interact in a complex fashion with most components of the immune system. Perhaps the processing of Ag, which they present to the other components, is one of these cells' most crucial function. The macrophage plays a role in recruiting and stimulating T cells during this process. In addition to a variety of antigen-dependent and antigen-independent interactions, the macrophage secretes numerous products. Of the several lymphokines, interleukin-1 (IL-I) has been reported to have a variety of functions and will be considered later.
B lymphocytes play a crucial role in their elaboration of immunoglobulin-plasma cells. Apparently, antigen selects B cell clones by interacting with surface immunoglobin of these clones. As shown in Figure 1 , these cells also respond to Th and Ts cells and are receptive to macrophages.
T lymphocytes play vital and different roles in these complex interctions. One subset, Th, is an inducer/ helper cell and is programmed to help other cells. They are activated by certain antigens associated with class I1 products of major histocompatibility types (e.g., macrophages and B cells). The other important and welldefined subset, Ts, is programmed as suppressor or killer cell and responds to class I products of major histocompatibility (e.g., all cells of the body). In addition, T cells are important for the lymphokines they produce.
. After reading this text and spending a few minutes following the interactions giving stimulation or feedback suppression, which may be dependent on antigen, antibody, or other cell types, one can appreciate the complexity of the immune responses to stress and to neoplastic growth.
Lymphokines
This rapidly evolving aspect of immune responsiveness must be appreciated in the context of the cell-cell interactions. At this time, purity, specificity of actions, and interdependency on other mediators or cells are just being unravelled. For example, a multitude of T-cell derived biologically active mediators (lymphokines) are induced by stimulation with specific heterologous antigens, alloantigens, or mitogens. These substances may be antigen-specific or nonspecific.
In addition to a variety of biologically active interferons, the interleukins are most important as mediators in regulating immune responsiveness. Macrophages secrete, among other things, interleukin-I, which stimulates T cell and B cell activity, regulates body temperature, etc. Most importantly, interleukin-1 stimulates production of interleukin-2 by T cells, which induces T cell proliferation. The interleukins act only on antigenactivated T cells. Other lymphokines, such as T cell growth factor, T cell replacing factor, and several others being defined from monoclonal antibody studies, require considerable elucidation. Considerable work is needed in defining the B cell lymphokines.
Immune Response of Cancer Patients
Over 20 years ago, Lamb and workers3' reported the relative state of anergy in patients with different malignancies. Soon after that, ~e w i s~' reported that the sera of patients with melanoma react against melanoma cells in a specific manner. Reconciling these earlier views of immune responsiveness was the report of Gillette and Boone,)' who related a decrease in mitogen response of lymphoid cells to progressive tumor growth.
As technologic advances have occurred, recent studies have focused on attempts to delineate specific defects in immune response and their relation to tumor type, stage, and burden.
In an extension of earlier work, Wanebo et a1.33 noted that 30% of patients with TlNoMo lesions were skin testnegative (to dinitro-chlorobenzene), and this per cent increased even further with more advanced lesions.
Bernengo and c o -a~t h o r s~~
reported a significant reduction in absolute T-Ea, T-Et, null cells, and total lymphocytes in patients who died of melanoma compared to. those who lived. Dellon, Elfenbein, and OrlandoY3' surprisingly, found decreased responsiveness of T cells to lectin mitogens in patients with basal cell carcinoma. With this defect disappearing after tumor removal, they suggested that the functional impairment was tumorinduced. This finding seems striking with such a small tumor burden. Perhaps the decrease in T cells found in patients is due to the sponge effect, as Kornstein and c o -~o r k e r s~~ found that lymphocytes in primary melanomas, metastases, and even dysplastic nevi were almost exclusively of the T4 (helper-inducer) and T8 (suppressorcytotoxic) type. On the other hand, Ravikumar and colleagues37 found in a rat tumor model that tumor growth was associated with a progressive increase in circulating immune complexes. Concomitantly, a decrease in production of interleukin-1 and -2 was found.
The variability of immunosuppressors may not only depend on tumor burden,38139 but may also vary with tumor type. As noted, ello on^' found immunosuppres-sion in patients with basal cell cancers. Humphrey, Singla, and Volenec4' found, however, that the peripheral blood lymphocytes (PBL) from breast cancer patients varied in their recognition of a breast cancer antigen, depending on the size of the primary lesion (e.g., PBL from patients with lesions < 2.4 cm did not recognize the tumor as foreign; those PBL in patients with lesions 2.5 cm-4.9 cm showed good lymphocyte stimulation; but PBL from patients with lesions > 5. cm showed immunosuppression). In a later comparative ~t u d y ,~' the PBL in patients with very thin melanomas recognized the melanoma antigen as foreign.
Taking into consideration the previous section delineating, even in simplistic fashion, the complexity and interaction of the immune system, this variety of immune responses to such diverse neoplasias should not be surprising.
Altered Immune Responsiveness Following Stress
In some rat experiments observing the effect of a major operation on the animals' resistance to cancer cells, Buinauskas and associates4' ( 195 8) inoculated two groups of rats with 25,000 Walker-256 cells; a celiotomy was performed on one group and the intestines stirred for 20 minutes. The take in the rats having the operation was twice as high as in the controls. These authors made no observations on human beings because no tests for the immune status were available at that time. This finding of decreased immune resistance produced by major operations for cancer does not detract from the value of surgical removal of cancer because that value is well-known.
Surprising as it may seem, opposing reactions often develop in cancer. In a recent study made by Cole43 of the 176 patients having spontaneous regression of cancer, as previously reported by Everson and observations were made for possible causative incidents. In the entire group of 176 cases, 7 1 patients (40%) had some type of operative trauma. This is such a high percentage that a definite significance appears likely, even though our rat experiments and the effect of major operations in human beings produced the opposite effect-suppression. Yet Kinnaert and associates4' have reported a stimulative immunologic effect of a celiotomy (without the additional trauma of stirring the intestines for 20 minutes).
In a more recent study of the literature, Cole' notes that during the past 10 or 12 years, a dozen or more authors had reported that major stimulation of the immune process during the immunosuppression produced by a major operation for cancer is a realistic goal. A few of these are discussed.
Park and associates, using tissue culture techniques, observed that in all of 21 patients having various types of major operations, the peripheral blood lymphocytes developed "depressed immunological competence as reflected by their diminished ability, under maximal stimulation with phytohaemagglutinin to incorporate Cthymidine and synthesize DNA."46
Following multiple parameters of in vivo and in vitro immune functions in 12 normal individuals having nephrectomy for renal transplant, Slade and associates have stated: "All in vitro functions studied (total blood lymphocyte count, B cell count, T cell count, mitogen blastogenic response, and mixed leukocyte reactivity) decreased on induction of anesthesia and continued to fall during and after ~peration."~' By the fifth postoperative day, all patients had near-normal function.
Jubert and associates48 noted that anesthesia, surgical procedures, and blood loss in the human being were followed by immunosuppression. They concluded that the magnitude of the surgical procedure and associated intraoperative blood loss correlated with thz degree of imunosuppression seen after surgery in humans.
Working with the human being, Lundy4' also noted that anesthesia and surgery produced immunosuppression and, in fact, that all therapeutic modalities are associated with immunosuppression. He states that "by removal of gross tumor in many patients, a restoration of general immune responses can be documented." Also, Lundy noted that "circulating antigens or antigen-antibody complexes'that block tumor-specific immune responses can be abrogated by removal of bulk tumor." He arrived at the conclusion that certain anesthetic agents and major procedures may enhance growth of micrometastatic tumor foci.
. Roth and associate^'^ state that "intraabdominal and intrathoracic procedures, transfusions, and long operative times depressed the lymphocyte proliferative response," although they noted an increased lymphocyte proliferation in patients with sarcoma. Many of these changes lasted for weeks after operation.
Cole and associates5' studied the results of four different groups comparing the 5-year survival in patients with obstructing and nonobstructed cancer of the colon. This is a different type of trauma than previously described. In the four groups, there were 199 patients with obstruction and 868 without obstruction. The 5year survival in the obstructed group was 27%, but in the nonobstructed group it was twice as high, 56%. It is not clear why this marked difference occurred. It is possible that the low survival rate in the obstructed cases was due to the trauma of increased peristalsis, which could disseminate more cancer cells. The group with obstruction of the bowel did not have more protracted symptoms.
In attempting to delineate the defect caused by trauma, Wood and co-workerss2 reported that, within 10 days of major thermal burn, peripheral blood lymphocytes from patients showed a decrease in number of T cells that was paralleled by a decrease in their function. Cellmediated immunity was measured by skin sensitivity to DNCB in mice with full-thickness burns.53 Severe immunosuppression was noted, but the anti-inflammatory drugs, ibuprofen, indomethacin, or cyclophosphamide restored immune responsiveness by inhibiting the production of T cells. Lukomska et aLS4 studied NK activity of PBL in 15 patients with ovarian cancer. NK activity was decreased 24 hours after surgery and slowly returned to normal at 7 to 9 days. Interferon was able to override the suppressive effect of glucocorticoids in a study reported by Holbrook, Cox, and Homer." These investigators found that PBL incubated in vitro with glucocorticoids caused a decrease in NK activity. The addition of interferon was able to override this effect.
Thus, the cancer patient undergoing surgery is exposed to an acute immunosuppression from stress at a time of maximal manipulation and in a host that, at least with some tumors, already is experiencing poor immune responsiveness.
Immunosuppression
The number of drugs and activities that have been found to increase the growth of tumors by suppressive effect has increased rapidly during the last 2 o r ' 3 decades.
Suppressive Agents and Procedures
This reaction occurs after most anticancer compounds, including antimetabolites, alkylating agents, purine analogues (including immuran), 6-mercaptopurines, and others. Other agents or drugs such as yeast extracts, cyclophosphamide, cyclosporine A, carbamazole, anti T cell reagents, and many more are, likewise, immunosuppressive. The immunosuppressive effect of many of these drugs was discovered in the process of trying to find drugs that would prevent graft rejection.
The occasional production of cancer by the immunosuppressive period associated with organ transplants is well-known and ~ersists.'~ Of 'special interest is the report by Krikorian and associates," stating that between January 6, 1968 and April 1977, 124 patients underwent cardiac transplantation at Stanford University Medical Center. Malignant neoplasms developed in seven patients (three lymphoproliferative neoplasms, two skin cancers, one leukemia, and one colon cancer). Visceral tumors were often fatal and caused 11% of deaths within 3 months following transplantation. The incidence of malignancy in this population is similar to that observed in recipients of renal homografts.
Numerous procedures and facilities we have considered innocuous 'have proven to be suppressive. For example, Anderson and BarrettS9 have reported that ultrasound is suppressive to mice when the splenic area is exposed to 2-M HZ ultra sound wave at a maximum intensity of 8.9MW/cm2. As a test for suppressive activity, they used "an injection of sheep's erythrocytes with hemagglutinin log2 titers." Also, "the difference in immunoglobulin levels of ultrasound-exposed mice compared to normal mice was reflected by the lowered number of direct antibody plaque-forming cells in the spleen of the treated animals." Immunosuppressive effects were not noted when the ultrasound energy was applied to the thighs of mice.
Tolerance
Specific unresponsiveness was characterized years ago. Only recently with the separation of PBL subsets and mediators have elaborate studies on immune-suppression, a nonspecific unresponsiveness, been camed out. Tursz et aL60 reported that the decreased NK activity of patients with malignant lymphoma did not correlate with age, extent of disease, or leukocyte count. They interpreted this to mean that NK cells played a role in surveillance. Of most significance to this subject is the evidence which suggests that tumors elaborate immunosuppressive substances. For example, ovarian cancers produce a protein which, in vitro, depresses lymphocyte blastogenesis to PHA and also suppresses mixed lymphocyte rea~tions.~' Nimberg and workers6* noted a peptide fraction from patients with other types of solid cancers and found that this fraction also suppressed lymphocyte blastogenesis of PBL. Similar suppressive activity was found in the ascitic fluid in patients with cancer metastatic to the pe~itoneum,6~ Roth and co-investigator~~~ extracted immunoregulatory factors from a variety of solid human tumors. These factors suppressed a variety of cell-mediated immune responses and, regardless of tumor type, possessed similar biochemical and immunobiological characteristics. These data along with the data on immunosuppression following stress must enter into the equation when considering the patient's immune responsiveness.
Suppressor Cells
R~t h~~ has very effectively reviewed tumor-induced immunosuppression, and has calledhattention to the fact that, in addition to the numerous cells effective in destroying cancer cells, there are suppressor cells (Gershon et a1.66) which can suppress cell-mediated immunity and antibody production. "Furthermore, they have a characteristic cell surface phenotype for cells of both mice, Ly2, 3, and human beings." Both antigen-specific and nonspecific cells have been identified. Most sup-pressor cells identified in animals are either macrophagemicrocytes or T cells.
The mechanism by which suppressor cells develop inhibition of immune responses is not clear, but it is thought that soluble mediators elaborated by these cells are important factor^.^' It has been shown that giving cyclophosphamide or low doses of radiation therapy will eliminate or destroy some of the suppressor Hersh and associates67 have detected suppressor cells in 7 1% of 35 patients with solid tumors and leukemia, when peripheral blood mononuclear cells from these patients were cocultured with phytohemagglutinin. This suppression activity could be blocked by low dose radiation, thymosin fraction 5, or thymus humoral factor.
Immune Stimulation
From consideration of data on immune suppression by stress and tumors, the interaction of components of hosts' immune systems, as depicted in Figure 1 , must encompass additional factors that may abrogate, enhance, or inhibit these interactions. As depicted in Figure 2 , a decrease or neutralizing of suppressor agents or components may result in immune stimulation similar to the direct enhancement of immune stimulatory components. Surprisingly, some chemotherapeutic agents may have such actions (e.g., cytoxan impairs Ts activity without equally impairing other T cell a~tivity).~' Macrophages have been shown in mouse tumor systems to possess nonspecific and tumor-specific activity in destroying celk70 Wood and Gillespie7' showed that tumor suspensions with macrophages, when injected into mice, grow slower and the mice survived longer than mice receiving tumor suspensions without macrophages. Similarly, Bartocci et aL7' used immunoaugmentating agents (such as levan, lentinan) to enhance macrophage and NK activity. Associated with this response in the mice were significant increases in delayed type hypersensitivity responses.
A variety of agents have been shown to modulate immune response; e.g., interferon increases NK cell cytotoxicity and killing of already bound tumor targets,73 levamisole exerts a growth-inhibiting effect on tumors via cytotoxic T cell^,'^ Corynebacterium parvurn activates both NK cells and macro phage^,^' and the ARA-nucleotides produce immunostimulation by a selective, toxic effect on Ts cells. 76 Bacillus Calmelte-Guerin (BCG) is a nonspecific stimulant to the immune system but its action is not known. Using a specific protein from allogeneic tumor tissue (VII) and in a more favorable setting, Humphrey and colleagues4' showed PBL from stage I and I1 melanoma and breast cancer patients could be stimulated. These patients were immunized after surgery in adjuvant immunotherapy trials and their PBL studied in lymphocyte blastogenesis showed good stimulation to the tumor extract. R e~e n t l y ,~~ subsets of PBL from these patients were correlated with LB Assay to VII. When VII was below normal (<0.8), Ts was 29.2; when VII was normal (0.9-1.4), Ts was 28.3; when VII was elevated (> 1.5), Ts was 24.6. NK also decreased from 21.4 to 18.1 to 17.6, respectively, while Th remained the same. Hence, a specific stimulation with tumor antigen is associated with both a decrease of suppressor lymphocytes and NK cells.
Ghanta and associates7' reported that prednisalone plus melphalan administered to mice with a myeloma tumor produced greater survival than when melphalan was given alone. They offered an unusual hypothesis suggesting that the increased tumor growth secondary to prednisalone made the cells more vulnerable to cytotoxic effects of melphalan. One might speculate that chemotherapy, in killing some tumor cells, releases other factors which inhibit interleukin-2 production, as reported by Hersey et a1.,79 and thereby depresses immune response even more than the direct marrow suppressive effects of the chemotherapeutic agent. No single answer will suffice for so many variables. Hopefully, assays to define the important components will become more specific and facile in human studies. Obviously, such assays are necessary to understand the patient's immune status before undertaking immunostimulation, but they are crucial to understand and correlate clinical results with immune responsiveness.
Clinical Trials of Immunostimulation
Regression of human tumors by immunostimulation has been noted by clinicians since early in the century. Coley's toxins were noted to result in an anti-tumor effect and were associated with significant local and systemic effects of infection. Hence, the use of microorganisms and their products to stimulate immune responsiveness and control cancer is well-do~umented.'~ In the last 2 decades, this renewed interest has been prompted by Old et a1." and Biozzi and w~rkers,'~ who showed that BCG increased immune resistance against experimental animal tumors.
Over the years, numerous studies have been carried out but clinical data have not shown any significant effect of this agent (BCG) on survival of the cancer patient. A few studies, however, have produced sufficient response, albeit small, to encourage continued eff o r t~. "~-~~ In fact, these results have lead to trials with other agents that have a known effect on specific components of the immune system. Thus, C. parvum, which depresses Ts cells, has been reported by Lipton et a1. 86 to be superior to BCG. In a randomized study using BCG or C. parvum for stage I and I1 patients, a 60% disease-free interval in those receiving C, parvum compared to 20% for those treated with BCG was noted in stage 11. In this adjuvant study, no difference was noted in stage I patients randomized to receive BCG or C, parvum. Using Mycobacterium smegmatis as adjuvant immunotherapy in patients following resection of primary lung carcinoma, Decroix and colleagues87 failed to find a significance in patients receiving M. smegmatis compared to controls. In similar fashion, levamisole8' has produced small effects but has had significant systemic reactions.
After numerous studies, nonspecific immune stimulators, while producing an occasional, small advantage to the patient, seem limited in their potential as single agents for increasing immune responsiveness.
Use of tumor-associated or tumorspecific products in clinical trials have been limited in number but have produced more encouraging data. Stewart et al.," using a cell membrane fraction, noted a significant response in the cancer patient. In adjuvant immunotherapy trials, Humphrey In similar trials using a cell cytoplasmic fraction from allogeneic melanoma tissue, they reported a 90% 5-year survival rate for stage I and 68% for stage I1 patients with malignant rnelan~ma.~' Many more investigations have utilized lymphocytes or their products in clinical trials. Pilch popularized the use of immune RNAg2 and noted favorable results in many patients, especially those with adenocarcinoma of the kidney. 92 Transfer factor has been used by LoBuglio et al?3 and Neff and Ennekix~g~~ in treating patients . with sarcoma, and by Jewel1 and colleagues95 with no real clinical response.
As technology has advanced, so has the sophistication of materials used in clinical trials. For example, Dye and North96 passively transferred sensitized T cells in an animal model and noted complete regression of the primary tumor, as well as destruction of metastases. Thus, preliminary clinical trials have been carried out using prostaglandin-sensitized mononuclear cells,97 lectinactivated mononuclear cells,98, lymphocytes cultured in T cell growth fact or, !' 9 and autologous cultured T cells.100 With advanced laboratory technology, these studies perhaps offer the most hope in determining and correcting the defect in immune response of the cancer patient following surgery.
Conclusion
As illustrated in Figure 2 , immunostimulation may be effected by a diminution of immunosuppressive agents. This is typified by the finding of Rossen et a1.I0' These investigators found survival time much shorter in melanoma patients (10 months) with circulating immune complexes in their sera compared to those patients with no demonstrable complexes (16 months) . These data support the work showing a decrease in pulmonary nodules following plasmapharesis. lo2 Thus, the use of immunostimulation for the patient with cancer very likely will depend on the special immune responsiveness and tumor burden of the host, along with the immunobiologic characteristics of the different tumors. As noted in this limited review, laboratory advances may well give us criteria in choosing the type of immunostimulation. This may take the form of (1) reducing tumor burden, (2) decreasing' tumor antigens and circulating immune complexes, (3) inhibiting Ts or suppressive mediators, or (4) enhancing Th, Tcyto, and immunostimulatory mediators.
The current developments in the search for immunostimulants are summarized in Table 1 . This variety of agents and their differing mechanisms of action, of which many are tenuously defined, reflects only the infancy of the most complex, crucial, and fascinating adjuvant for the surgeon.
